Nurix Therapeutics PE Ratio 2019-2021 | NRIX

Current and historical p/e ratio for Nurix Therapeutics (NRIX) from 2019 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Nurix Therapeutics PE ratio as of November 29, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Nurix Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-11-29 28.88 0.00
2021-08-31 32.19 $-2.39 0.00
2021-05-31 27.90 $-2.33 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.341B $0.018B
Nurix Therapeutics a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics based in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09